Histologic subtype of treatment failures after noninvasive therapy for superficial basal cell carcinoma: An observational study - 14/03/19
Abstract |
Background |
There have been concerns that recurrences after noninvasive therapy for basal cell carcinoma (BCC) transform into a “more aggressive” histologic subtype.
Objective |
We sought to evaluate the proportion of patients with a nonsuperficial treatment failure after noninvasive therapy for superficial BCC.
Methods |
An observational study was performed using data from a single blind, noninferiority, randomized controlled trial (March 2008-August 2010) with 5-year follow-up in patients with primary superficial BCC treated with methylaminolevulinate–photodynamic therapy, 5-fluorouracil, or imiquimod. Data were used from 166 adults with a histologically confirmed treatment failure.
Results |
A nonsuperficial subtype was found in 64 of 166 treatment failures (38.6%). Proportions with a more aggressive subtype than the primary tumor were 51.3% (38/74) for early and 28.3% (26/92) for later treatment failures (P = .003). The proportion of more aggressive early failures was significantly lower after imiquimod (26.3%) compared with methylaminolevulinate–photodynamic therapy (54.8%, P = .086) and 5-fluorouracil (66.7%, P = .011).
Limitations |
There was limited information on the exact time of occurrence of treatment failures.
Conclusion |
More aggressive treatment failure recurrences after noninvasive therapy for superficial BCC occur most often within the first 3 months posttreatment, probably indicating underdiagnosis of more aggressive components in the primary tumor rather than transformation.
Le texte complet de cet article est disponible en PDF.Key words : 5-fluorouracil, basal cell carcinoma, histologic subtype, imiquimod, MAL-PDT, misclassification, noninvasive therapy, sampling error, superficial, transformation
Plan
Data herein were used from a trial that was supported in part by a grant from ZonMW (registered as an International Standard Randomized Controlled Trial [ISRCTN 79701845]). |
|
Conflicts of interest: None disclosed. |
|
Reprints not available from the authors. |
Vol 80 - N° 4
P. 1022-1028 - avril 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?